Table 4 The GEE model for LLV events (defined as 50–199 copies/ml) of developing VF Events (defined as ≥ 200 copies/ml)

Male (vs. Female)

0.395 (0.168, 0.928)

‒60.5 (‒83.2, ‒7.2)

0.033

Age > 25 (vs. < 25 years)

1.634 (0.927, 2.882)

63.4 (‒7.3, 188.2)

0.090

Homosexual Transmission (vs. other)

1.664 (0.79, 3.505)

66.4 (‒21, 250.5)

0.180

Time from diagnosis to treatment ≤ 1 (vs. > 1 months)

1.221 (0.744, 2.002)

22.1 (‒25.6, 100.2)

0.429

CD4 + T cell count ≤ 200 (vs. > 200 cells/µL)

1.108 (0.629, 1.952)

10.8 (‒37.1, 95.2)

0.723

Viral load at baseline > 100,000 (vs. ≤ 100,000 copies/mL

1.312 (0.714, 2.408)

31.2 (‒28.6, 140.8)

0.381

LLV events during follow-up. (Yes vs. No) ^a

2.235 (1.075, 4.644)

123.5 (7.5, 364.4)

0.031

INSTIs-based regimen (vs. PIs-based regimen)

0.231 (0.131, 0.409)

‒76.9 (‒86.9, ‒59.1)

< 0.001